Saturday 17 October 2026
Export TLRY’s income statement to Excel — free account
Tilray Brands, Inc.
TLRY Healthcare Drug Manufacturers Specialty & Generic
Tilray Brands, Inc.’s revenue for fiscal 2026 (year ended May 2026) was $915.5 million, up 11.5% from fiscal 2025. In the quarter to August 2026, revenue grew 22.7%, EPS was flat, free cash flow fell 36.6% and total debt rose 43.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.04
0.17
−5.30%
Follow TLRY
| Older periods | Nov '25 | Feb '26 | May '26 | Aug '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
3 | 3 | 3 | 4 |
| (84.30%) | (63.61%) | (7.87%) | (10.50%) | ||
| (67.01%) | (49.09%) | (5.52%) | (7.45%) | ||
ROIC |
(89.19%) | (59.65%) | (2.27%) | (3.21%) | |
Return on Tangible Assets |
(206.60%) | (133.90%) | (10.90%) | (15.75%) | |
Average Days of Receivables |
47.55 | 50.34 | 75.42 | 72.24 | |
Free Cash Flow per Share |
(0.56) | (1.14) | (0.88) | (1.31) | |
Free Cash Flow |
(61.79) | (128.34) | (98.62) | (174.45) | |
Capital Expenditures |
(33.34) | (83.71) | (29.48) | (90.10) | |
| Other line items | |||||
Cash ROIC |
(2.89%) | (6.14%) | (4.47%) | (8.00%) | |
Accounts Receivable Turnover |
7.55 | 7.74 | 5.89 | 6.47 | |
Accounts Payable Turnover |
2.69 | 2.82 | 2.37 | 2.41 | |
Inventory Turnover |
2.19 | 2.23 | 2.29 | 2.23 | |
Average Days of Payables |
137.12 | 131.72 | 177.25 | 179.35 | |
Days of Inventory on Hand |
171.50 | 171.88 | 167.84 | 175.90 | |
Tax Rate |
(0.06) | (0.08) | 0.19 | 0.17 | |
Research and Development Expense of Revenue |
0.03% | 0.03% | 0.04% | 0.04% | |
Selling, General and Administrative Expense of Revenue |
30.84% | 31.20% | 32.25% | 33.02% | |
Share Based Compensation of Revenue |
3.28% | 4.33% | 5.02% | 4.93% | |
Interest Coverage |
(91.10) | (70.98) | (2.66) | (3.80) | |
Operating CF/Net income |
0.01 | 0.03 | 0.57 | 0.51 | |
Depreciation/Fixed assets |
0.20 | 0.17 | 0.11 | 0.12 | |
Capex/Depreciation |
(0.31) | (0.90) | (0.39) | (1.15) | |
Revenue per Share |
7.59 | 7.62 | 8.19 | 7.22 | |
Operating CF per Share |
(0.26) | (0.40) | (0.62) | (0.63) | |
Capex per Share |
(0.30) | (0.74) | (0.26) | (0.68) | |
Capex to Sales |
0.04 | 0.10 | 0.03 | 0.09 |
Columns are period end dates · fundamentals updated 13 Oct 2026